Recall Record: Class II Recall: CLINDAMYCIN PHOSPHATE by Baxter Healthcare Corporation

Key facts

What consumers should do

Facilities, clinicians, and consumers holding an affected unit or lot of Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Manufactured by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-4114-50. should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Baxter Healthcare Corporation. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Baxter Healthcare Corporation should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Baxter Healthcare Corporation directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.

What this classification means

A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.

Baxter Healthcare Corporation’s FDA history

Argus HQ has recorded 231 total FDA actions tied to Baxter Healthcare Corporation: 0 warning letters, 231 recalls, 0 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

Why was Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 m recalled?

FDA's recall record states the reason as: CGMP Deviations

Who should I contact about this recall?

Contact Baxter Healthcare Corporation directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.

Has Baxter Healthcare Corporation had other FDA recalls or enforcement actions?

Yes. Argus HQ has recorded 231 total FDA actions tied to Baxter Healthcare Corporation, including 231 recalls and 0 warning letters.

What is the FDA recall number for this event?

FDA recall number D-0817-2026.

Related enforcement actions

• Recall: Baxter Healthcare Corporation — Class I recall: Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporat… →
• Recall: Baxter Healthcare Corporation — Class II recall: Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg… →
• Recall: Baxter Healthcare Corporation — Class II recall: Vancomycin Injection, USP in 5% Dextrose, 1 g per 200mL (5 mg/mL), in GALAXY Sin… →
• Recall: Baxter Healthcare Corporation — Class II recall: Pantoprazole Sodium in 0.9% Sodium Chloride Injection, 80 mg/100 mL (0.8 mg/mL)… →
• Recall: Baxter Healthcare Corporation — Class II recall: Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY… →
• Recall: Baxter Healthcare Corporation — Class II recall: Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg/mL), 1… →
• Recall: Baxter Healthcare Corporation — Class II recall: CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg… →
• Recall: Baxter Healthcare Corporation — Class II recall: Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 400 mcg per 100… →